Inflammation plays a critical role in cystic fibrosis (CF) lung pathology and disease progression making it an active area of research and important therapeutic target. In this review, we explore the most recent research on the major contributors to the exuberant inflammatory response seen in CF as well as potential therapeutics to combat this response. Absence of functional cystic fibrosis transmembrane conductance regulator (CFTR) alters anion transport across CF airway epithelial cells and ultimately results in dehydration of the airway surface liquid. The dehydrated airway surface liquid in combination with abnormal mucin secretion contributes to airway obstruction and subsequent infection that may serve as a trigger point for inflammation. There is also evidence to suggest that airway inflammation may be excessive and sustained relative to the infectious stimuli. Studies have shown dysregulation of both pro-inflammatory mediators such as IL-17 and pro-resolution mediators including metabolites of the eicosanoid pathway. Recently, CFTR potentiators and correctors have garnered much attention in the CF community.
IL-6, IL-8, IL-17, IL-33, GM-CSF, G-CSF, and HMGB-1. 6 IL-17, which has been the focus of much recent research, is markedly increased in the CF lung and promotes inflammatory cell signaling in response to noxious stimuli. 7, 8 IL-17 is an important molecule in host defense, but if it is present in excessive amounts, particularly once chronic infection is established, it may contribute to immunopathology through its ability to promote neutrophil influx. CF mice had greater concentrations of IL-17, pro-inflammatory cytokines, and neutrophils isolated from bronchoalveolar (BAL) fluid than did wild-type (WT) mice despite similar bacterial burdens. 9 When CF mice received monoclonal antibody to inhibit IL-17, they had improved weight gain, decreased BAL neutrophils, decreased production of pro-inflammatory mediators, and decreased bacterial burdens compared to CF mice that received injections of control intravenous IgG. 9 These data suggest that the IL-17 signaling pathway is dysregulated in CF and could be a potential target for anti-inflammatory therapy. However, before inhibiting IL-17 in people with CF, it is important to consider its contributions to host defense. Bayes et al demonstrated that signaling is crucial in host defense against initial P aeruginosa infection and protects against the establishment of chronic infection. 10 Infected mice lacking the IL-17 receptor had less weight loss but increased bacterial burdens compared to WT mice. Infection rates 2 weeks after inoculation with P aeruginosa were 25% in WT mice and 100% in IL-17 receptor knockout mice. 10 In another study, Lorè et al used the agarose-bead model of P aeruginosa infection in mice to evaluate the role of IL-17 during the early and late stages of infection. 11 They found that concentrations of IL-17A remained elevated throughout the course of the infection. During the early periods of infection, IL-17 appeared to be important in the host's ability to manage bacterial infections. IL-17 knockout and IL-17 receptor knockout mice had difficulty clearing bacterial infections, had increased bacterial burdens, and were more likely to go on to develop chronic infection; however, the investigators found that increased concentrations of IL-17 may be detrimental during later stages of the infection. Once chronic infection had been established, IL-17 knockout and IL-17 receptor knockout mice had reduced pro-inflammatory cytokine concentrations and tissue damage compared to control mice. 11 In order to evaluate the impact of IL-17 inhibition during late stages of P aeruginosa infection, the investigators administered anti-IL-17 monoclonal antibody to chronically infected WT mice. There was no increase in the bacterial burden in treated mice, but there were reductions in inflammatory mediators and markers of tissue remodeling and damage. Taken together, these data suggest that if IL-17 is to be considered as a therapeutic target for antiinflammatory drugs in CF, the potency and possibly timing of IL-17 inhibition may be crucial to prevent infectious complications.
Although most research into CF airway inflammation has focused on the activation arm of the inflammatory response, several researchers have directed their attention toward the termination or resolution phase. It does not appear that there is an abnormality in activating the inflammatory response in CF. Once activated, airway inflammation often increases dramatically and becomes self-perpetuating. One might then logically conclude that the abnormality is in terminating or resolving the pro-inflammatory state. Although the pro-inflammatory metabolites of arachidonic acid metabolism have been the scrutiny of much scientific inquiry in lung diseases, metabolites of the eicosanoid pathway that promote resolution of inflammation are garnering increased attention in inflammatory diseases, including CF. These pro-resolving mediators appear to be deficient in CF airways. [12] [13] [14] The imbalance between eicosanoid proinflammatory and pro-resolving metabolites in CF favors the development of chronic inflammation ( Figure 1) . In mouse models of inflammation, pro-resolving mediators decreased neutrophil influx into sites of inflammation, improved the clearance of apoptotic neutrophils by macrophages, and reduced the activation of nuclear factor-kappaB (NFĸB). 15 Lipoxin A4 (LXA4) and the docosahexaenoic acid (DHA)
metabolite Resolvin D 1 (RvD1) have been the focus of recent investigation in CF. The concentration of RvD1 reflects the underlying lung disease severity and eventually may serve as a useful biomarker.
RvD1 was present in both the plasma and sputum of people with CF. 16 In this study, there was positive correlation between plasma and sputum RvD1 concentrations, but plasma concentrations were 10-fold greater than sputum concentrations in people with CF. These results suggest that RvD1 exerts its effects distally as well as locally.
Concentrations of RvD1 in sputum also demonstrated significant positive correlation with sputum neutrophils, IL-1β, and IL-8. Although
RvD1 was present in CF sputum, its increase was not proportional to increases in sputum IL-8. The ratio of RvD1/IL-8 positively correlated
with FEV 1 , indicating that an imbalance between RvD1 and the proinflammatory mediator it down-regulates may associate with progressive lung deterioration. 16 Ringholz et al evaluated the impact of RvD1 on airway surface liquid (ASL) height and innate defense in CF. 17 Application of RvD1 to primary CF bronchial epithelial cells and to CF cell lines increased ASL height in a dose-dependent fashion, likely through the inhibition of the epithelial sodium channel (ENaC) and other ion transport pathways, rather than through a direct effect on cystic fibrosis transmembrane conductance regulator (CFTR). In nasal transepithelial electrical potential difference (NTEPD) studies, application of RvD1 to the nasal mucosa was associated with reduced amiloride-sensitive NTEPD in CF mice but not WT mice. When RvD1 was added to the nasal infusion fluid of CF mice, the NTEPD response to chloride-free solution was significantly increased. The NTEPD data suggest that exogenous RvD1 stimulates chloride secretion through a channel other than CFTR while simultaneously inhibiting ENaC.
Ringholz et al also evaluated the impact of RvD1 on host defenses. 17 When CF alveolar macrophages were treated with RvD1, there was increased phagocytosis of labeled beads compared to vehicle treated alveolar macrophages. There was also a significant reduction in intracellular viable P aeruginosa in CF alveolar macrophages that were pre-treated with RvD1 compared to those pre-treated with vehicle, thereby demonstrating the importance of RvD1 in host defense.
Codagnone et al evaluated the effect of exogenous RvD1 administration on the lung inflammatory response using the P aeruginosa agarose-bead model. 18 During the acute stage of infection, RvD1 decreased bacterial growth and neutrophil influx into the lungs, and during the chronic stage of infection, RvD1 decreased bacterial burden and leukocyte infiltration while limiting tissue destruction. 18 The investigators also studied the 18 These studies support the notion that dysfunctional CFTR and the dysregulated inflammatory response in CF are closely associated and that RvD1 holds potential as a therapeutic in CF due to its beneficial effects on ion transport, host defense, and immunoregulation.
Like RvD1, LXA 4 is a pro-resolving mediator of inflammation that is derived from the eicosanoid metabolic pathway. LXA 4 
Imbalance between pro-inflammatory and pro-resolving eicosanoid metabolites in cystic fibrosis (CF). Arachidonic acid (AA) is derived from omega-6 polyunsaturated fatty acids and primarily is associated with activation of the host inflammatory response. Docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) are derived from omega-3 polyunsaturated fatty acids and are primarily associated with resolution of inflammation and a return to homeostasis. In CF, AA is increased and DHA is decreased. AA predominately generates pro-inflammatory mediators, including the potent neutrophil chemoattractant leukotriene B4 (LTB4), but it also generates Lipoxin A4 (LXA4), a significant pro-resolving mediator. LTB4 is markedly increased, and its inhibitor LXA4 is markedly decreased in CF, which increases neutrophil influx into the airway. In addition, the pro-resolving mediator resolvin D1 (RvD1), a product of DHA metabolism, is markedly decreased in CF. Therefore, an imbalance between the eicosanoid pro-inflammatory mediators and pro-resolving mediators exists in CF, and activation of inflammation is favored over termination of inflammation. The resultant chronic neutrophil infiltration is responsible for much of the inflammatory pathophysiology associated with CF lung disease. An anti-inflammatory therapy that upregulates pro-resolution factors may have tremendous utility in CF. COX, cyclooxygenase; HDHA, hydroxydocosahexaenoic acid; HEPE, hydroxyeicosapentaenoic acid; HETE, hydroxyeicosatetraenoic acid; HPDHA, hydroperoxydocosahexaenoic acid; HPETE, hydroperoxyeicosatetraenoic acid; LOX, lipoxygenase; MaR, maresin; PD, protectin; PG, prostaglandin; PLA2, phospholipase A2; TX, thromboxane degranulation, NF-κB activation, macrophage efferocytosis, and release of IL-6 and IL-8. In addition, LXA 4 was recently shown to have protective effects against the disruption of CF epithelial cell tight junctions after exposure to P aeruginosa. 23 29 Inhibition of HDAC6 in mice challenged with lipopolysaccharide (LPS) reduced NF-κB activation and proinflammatory mediator (IL-6 and myeloperoxidase) production, and it increased activation of Nrf2, a counter-regulatory transcription factor. 29 In addition to promoting increased inflammation, HDAC6 also appeared to adversely impact growth. 30 To study the effects of HDAC6 on growth, transgenic F508del/HDAC6-knockout mice were developed. These mice had improved length and weight measurements despite abnormal CFTR function. Increased IGF-1 expression likely accounted for the improvements in length, and increased fat deposition likely accounted for the improvements in weight in these mice. Thus, HDAC6 activation might contribute to the growth abnormalities seen in CF. Given these results, HDAC6 presents a tempting therapeutic target for CF. Although membrane cholesterol content appears increased in CF epithelial cells, it seems to be decreased in circulating neutrophils from people with CF. Membranes of CF neutrophils contained less cholesterol but possessed increased CD11b expression. 31 Endoplasmic reticulum stress responses activated μ-calpain in CF neutrophils, which subsequently resulted in proteolysis of caveolin-1, a membrane cholesterol trafficking protein.
Decreased circulating mediators, increased caveolin-1, and increased membrane cholesterol content were found when investigators studied neutrophils from people with CF who underwent lung transplantation or who carried at least one G551D mutation and were being treated with ivacaftor. 31 The findings of decreased circulating mediators and increased caveolin-1 and cholesterol content are noteworthy because abnormal membrane cholesterol content adversely effects neutrophil adhesion. Subsequent treatment with ivacaftor was associated with reduced neutrophil adhesion. Differences in the results from studies that evaluated membrane cholesterol content in epithelial cells and neutrophils are likely due to differences in the methods used to measure membrane cholesterol content and differences in the model systems, including the cell type being studied, the amount of cholesterol synthesis by each cell type, the influences of the local milieu, the expression of CFTR, and other parameters. Regardless of these differences, it appears that cholesterol trafficking and membrane cholesterol content are important in the CF airway inflammatory response and are deserving of further scientific investigation.
| ASSOCIATIONS BETWEEN ABNORMAL CFTR AND AIRWAY INFLAMMATION
The relationship between abnormal CFTR function and the develop- CF pigs were more likely to be positive for bacteria than were cultures from the lungs of newborn non-CF pigs. 32 Furthermore, when aerosolized bacteria were introduced into the lungs of older pigs, CF pigs were less likely to clear the bacteria than were non-CF pigs; these data suggest that the CF lung has a proclivity to become infected with bacteria and once infected, is less able to eradicate the airway infection. 32 A recently published study in ferrets suggests that inflammation might occur in the absence of infection. 33 CFTR knockout ferrets and their non-CF littermates were treated with three antibiotics from birth until 1-4 years of age. Despite the absence of bacteria, CF ferrets developed bronchiectasis, neutrophil mediated inflammation, and increased MUC5B accumulation. 33 The presence of mucus alone appears to be sufficient to trigger the exuberant inflammatory response in CF. In an associated study, continuous antibiotic treatment in CF ferrets was associated with improved survival compared to CF ferrets that received intermittent antibiotics for increased symptoms. 33 Taken together, the results from studies early in life using the CF ferret model call into question whether persistent infection is required to maintain the heightened inflammatory response in CF and subsequently stimulate disease progression. It is plausible that bacteria cleared by antibiotic treatment in the ferrets triggered an inflammatory response that persisted and could not be properly down-regulated.
In addition to its effects on infection and inflammation, CFTR also plays a critical role in the regulation of ion transport across airway epithelial cells. When CFTR function is abnormal, the airway surface environment is altered. Because obstruction, infection, and inflammation are so closely linked in CF, it is important to have a basic
understanding of the characteristics of airway surface fluid to determine how abnormalities in the local environment, particularly mucostasis, lead to the development of exaggerated host inflammatory responses. In CF, chloride movement into the airway lumen is impaired, and sodium absorption out of the airway lumen is increased resulting in increased water absorption and subsequent dehydration of the airway surface liquid. 34 Early models of the airway surface posited that rafts of mucus (gel), composed primarily of secreted mucins MUC5AC, MUC5B, and MUC2 which were tethered to cilia, floated on top of a watery periciliary layer (sol). 35 Inhaled pathogens and inert particles would land on the mucus, and ciliary beating propelled the rafts out of the lungs taking the noxious stimuli with them. However, recent data have challenged this conceptual model. A series of studies suggest that the periciliary layer is actually a second gel composed of MUC1, MUC4, MUC16, and possibly MUC20 that also are tethered to cilia. 36, 37 The periciliary gel is not uniform but more densely packed toward the epithelial cell surface. This thought construct is often referred to as the "two-gel model." The presence of interpenetrating mucins increases the ability to pull water into the periciliary gel layer to maintain hydration. 37 The periciliary gel allows the mucus layer to slide over it. The ability of mucus to slide on the periciliary gel is related to the hydration status of the periciliary layer. In CF, abnormal ion transport results in removal of water from the periciliary gel which leads to mucus hyper-concentration (increased percent solids), compression of the periciliary layer by the mucus layer, decreased mucociliary clearance, and adhesion of mucus to the airway walls. 37, 38 Recent data suggest that the secretion of MUC5AC and MUC5B into the airway lumen is abnormal in CF and contributes to airway obstruction. MUC5AC is produced in goblet cells and MUC5B
is produced in submucosal glands and to a lesser degree, goblet cells. [39] [40] [41] [42] [43] Ostedgaard et al studied the secretion of MUC5AC and MUC5B in freshly excised airways from uninfected CF and non-CF pigs. They found that "wispy threads" of MUC5AC, which occasionally formed sheets of mucins, were secreted from goblet cells and that strands consisting of multiple individual filaments of MUC5B were extruded from submucosal glands. 43 In addition, MUC5AC often coated strands of MUC5B. Several observations were seen in CF pigs compared to non-CF pigs: (1) MUC5AC formed sheets more frequently in CF pigs than non-CF pigs; (2) Sheets of MUC5AC were more likely to overlay strands of MUC5B; (3) Strands of MUC5B were more likely to remain attached to the submucosal gland ducts from which they arose;
and (4) Strands of attached MUC5B often became entangled. 43 The failure of MUC5B strands to break free and leave the submucosal gland duct had been seen in another study. 44 It is easy to see how the differences in mucins seen in CF would further adversely impact mucociliary transport and contribute to airway obstruction. Clearly mucostasis from decreased mucociliary clearance and increased mucus adhesion worsen airway obstruction and serve as fertile ground for bacterial infection and a trigger point for an exaggerated inflammatory response. 33, 45, 46 Therapies that relieve airway obstruction will likely have beneficial effects on the airway inflammatory response as has been documented with the administration of dornasealfa and hypertonic saline. 47, 48 With MDMs to phagocytose and kill P aeruginosa. 54 Lumacaftor alone restored the ability of CF MDMs to phagocytose and kill P aeruginosa to levels observed in MDMs obtained from non-CF subjects. Although lumacaftor alone had no significant effect on P aeruginosa-stimulated attempted to address some of these questions. 56 In this single center study of 12 subjects in whom ivacaftor was initiated, a reduction in sweat chloride was seen 2 days after starting ivacaftor and was sustained throughout the study period. FEV 1 improved at day 2, day 7, and throughout the study. In those individuals infected with P aeruginosa, the absolute and relative abundance of P aeruginosa declined during the first year of treatment but then rebounded in eight subjects in year 2. Upon closer examination of the data, P aeruginosa colony counts started to increase at 7 months in six subjects. In contrast to the results of the GOAL study, 49 concentrations of inflammatory mediators, IL-1β, IL-8, and free neutrophil elastase, decreased in the first week of the study and continued to decrease over the course of the study, although they were still present in large amounts at the end of the study. It is important to note that the microbiology data were captured for longer periods of time (up to 975 days) than were inflammatory mediator data (up to 600 days). It is unclear what happens to inflammatory mediators at more remote times: Do they plateau? Do they continue to decrease? Or, do they increase to meet the demands of increasing bacterial burden? If inflammatory mediators continued to decrease in the presence of increasing bacterial colony forming units, spread to distal sites and secondary infectious complications would likely occur. If inflammatory mediator production increases to address the increasing infectious burden, it is conceivable that the inflammatory processes may continue to escalate such that the CF airway inflammatory response once again becomes excessive relative to the bacterial burden. In the discussion of the manuscript, the authors reviewed possible explanations for why the results of this trial were different than those from the GOAL study. 56 Fewer subjects in the GOAL study were infected with P aeruginosa. It is possible that the change in P aeruginosa density drove the reduction in the inflammatory markers, which is concerning given the rebound seen in the second year. There were also technical differences in sputum processing. In GOAL, sputum was obtained via induction with inhaled hypertonic saline and frozen so it could be shipped to a central laboratory for processing. The single center study in Dublin used spontaneously expectorated sputum samples that were processed immediately without freezing into fractionated cell pellets and supernatants. Perhaps these differences in sample collection and processing contributed in some way to the inconsistent results. These differences must be reconciled because further research is now being would be impossible to review all of the data here; therefore, we have chosen to focus on neutrophils, macrophages, and T-lymphocytes.
| Neutrophils
CF lung disease is characterized by a neutrophil-predominate inflammatory influx. For decades, researchers have focused on neutrophils in CF, which is logical given the massive number of neutrophils present in the CF airway and the central role they play in generating and maintaining the excessive and damaging inflammatory response. In the CF airway, decomposing neutrophils release large amounts of intracellular contents,
including chemoattractants, which fuel further neutrophil influx, actin and long-stranded DNA, which contribute to the high viscosity of CF sputum, and reactive oxygen species (H 2 O 2 and O À 2 ) and proteases, including elastase, which damage the airway wall architecture. Neutrophils were once thought of as the pre-programmed foot soldiers of the acute inflammatory response: an infectious stimulus would enter the airway and the local sentry cells (epithelial cells and macrophages) would release mediators to call neutrophils into the lung where they would release their contents to minimize the threat from the invading organisms. Neutrophils would then undergo apoptosis. Clearly, neutrophil biology is more complex than that. Recent studies of neutrophils from people and mice with CF illustrate the tremendous plasticity of neutrophils. 57 Sixtyfold more IL-17-producing neutrophils were present in BAL fluid in CF mice after P aeruginosa challenge than were present in WT mice. 58 Large amounts of IL-17-producing neutrophils were also isolated in the peripheral circulation and sputum from people with CF at the start of intravenous antibiotic treatment for a pulmonary exacerbation due to P aeruginosa infection. In fact, most of the IL-17A isolated from the airway could be attributed to neutrophils.
CF neutrophils from blood and sputum also demonstrated increased IL-23-dependent cell surface expression of the IL-17
receptor (IL-17RC) at the onset of therapy for a pulmonary exacerbation, thus suggesting that IL-17A may work in both paracrine and autocrine fashions. The inverse correlation between percent IL-17 neutrophils and FEV 1 was also highly statistically significant. 58 The percentage of IL-17-producing neutrophils present in sputum after 2 weeks of intravenous antibiotic treatment decreased to approximately zero in nearly all study participants, thus suggesting that IL-17-producing neutrophils may be a good biomarker for CF pulmonary exacerbation. In addition to neutrophils themselves, one must also be cognizant of the effects of neutrophil products. As noted in the previous review, neutrophils are the source of the massive amounts of free elastase in the CF airway. 6 Elastase possesses several deleterious characteristics that account for much of the lung damage seen in CF. The amount of free elastase in the airway highly correlates with lung function (FEV 1 ). 59 Therefore, investigators have been attempting to develop an inhibitor of neutrophil elastase that can be produced in large quantities and be delivered efficiently and effectively to the airway surface. In addition to being free in the airway lumen, active neutrophil elastase can also be detected on the surface of neutrophils. Surface-bound elastase activity was increased on the surface of neutrophils from people with CF compared to healthy volunteers, and it correlated with free elastase activity and concentrations of other inflammatory mediators. 60 While both surface-bound and free elastase correlated with FEV 1 , only surface-bound elastase activity correlated with FRC. 60 Perhaps surface-bound elastase activity could serve as a biomarker for worsening lung hyperinflation. Given the central role of the neutrophil and its products in CF airway pathophysiology, an effective anti-inflammatory drug necessarily will have to address either the neutrophil itself or its products. due to decreased apoptosis than did non-CF neutrophils. 67 The opposite was found in people with G551D who were being treated with ivacaftor. The investigators also found that NETs provided a proinflammatory stimulus to macrophages, which was enhanced in CF. 67 The CF lung is an especially conducive environment for NETosis. Not only are neutrophils present in massive amounts, but infectious stimuli for NETosis are also abundant. Exposure of neutrophils to either LPS or P aeruginosa stimulated NETosis 66, 68 ; however, over time, P aeruginosa became resistant to NET-mediated killing. 69 Interestingly, motile, flagellated P aeruginosa were more likely to induce NETosis than were immotile, non-flagellated P aeruginosa, the most common form found in CF lung biofilms. 70 NET-mediated killing may be more relevant for bacteria that are in the planktonic state. In general, bacteria evade NET-mediated killing by several mechanisms including inhibition of NET formation through down-regulation of host inflammatory responses; degradation of NETs using pathogen-derived DNases;
and developing resistance to the microbicidal components of NETs. 71 Although NETs eventually become ineffectual in killing bacteria over time, they still are able to incite a vigorous and damaging inflammatory response. P aeruginosa-induced NETosis accounts for the release of many of the damaging neutrophil products into the airway, 72 further exacerbating the damaging lung inflammation. In addition, NETs stimulate pro-inflammatory mediator release from macrophages which then stimulate Th17 cells to produce chemokines to further fuel the influx of neutrophils. 73 Given the important role NETosis plays in CF 75 The relative hypoxia of the upper lobes compared to the lower lobes of the lung may trigger alterations of the microRNA content, particularly for miR-93, miR-4454, miR-451a, and miR-663a. 75 When exposed to 5% hypoxia, CF alveolar macrophages had increased production of TNF-α and IL-8, compared to when they were exposed to normoxic (21%) conditions. In order to determine if the functional deficits that have been described in CF macrophages were due to abnormal CFTR function or due to an acquired response from the local environment, Paemka et al studied MDMs from newborn CF and non-CF pigs in vitro. 85 By using monocytes from newborn pigs, the investigators were able to evaluate macrophage function before the onset of inflammation, and thus with CF have low expression of CD11b, a receptor for opsonic phagocytosis of many bacteria including P aeurginosa. 77, 86, 87 In addition, caveolin-1 is decreased in activated CF macrophages 88, 89 and likely inhibits the macrophage's ability to internalize P aeruginosa. 90 Some investigators suggest that the impaired ability of CF macrophages to kill bacteria in the phagolysosome is secondary to defective acidification from dysfunctional CFTR, 91, 92 although these findings are not universally observed. 93 In addition to intrinsic macrophage defects, environmental factors also impair the macrophage's ability to phagocytose bacteria. Removal of bacteria is mediated by opsonic and non-opsonic receptors and ligands that are present on the macrophage and the bacterial cell. These include IgG, complement, and complement receptors. Free elastase in the CF airway cleaves opsonins and the receptors of opsonins so that interaction between the ligand and its receptor cannot occur, 94, 95 which then prevents bacteria from being internalized. If there is internalization of the bacteria, bacterial killing in the phagolysosome may be hindered by the alkalinization of the phagolysosome which occurs from abnormal bicarbonate and chloride transport through defective CFTR. 92 Bone marrow-derived macrophages from F508del/ F508del transgenic mice had difficulty internalizing and clearing P aeruginosa. When macrophages were treated with cysteamine, a proteostasis regulator that rescues F508del function, there was reduced pro-inflammatory mediator (TNF-α and IL-1β) production and improved uptake and clearance of P aeruginosa. 96 Alveolar macrophages and MDMs from people with CF and healthy volunteers were studied ex vivo. 97 CF macrophages were unable to clear B cenocepacia due to defective autophagy. Administration of cysteamine increased direct bacterial killing. In addition to improved bacterial clearance through direct killing effects and autophagy, cysteamine was associated with decreased inflammation and decreased production of reactive oxygen species. 97 These studies suggest that the impaired phagocytosis seen in CF macrophages may be directly related to abnormal CFTR function. Once that function is restored, phagocytosis is re-established.
In addition to removing bacteria by phagocytosis, macrophages also dispose of debris and apoptotic cells through efferocytosis.
However, increased proteases in the airway impede efferocytosis by cleaving phosphotidylserine receptors from the macrophage cell surface. 98, 99 Macrophage phagocytosis of apoptotic neutrophils leads to upregulation of the scavenger receptors CD206 and macrophage receptor with collagenous structure (MARCO), which are important in internalizing non-opsonized particles. CD206 and MARCO are decreased on sputum macrophages from people with CF. 100 The inability to remove apoptotic cells further impedes resolution of the inflammatory response, even once the pathogen has been neutralized.
Studying macrophage biology is quite complex. Results from seemingly similar experiments give incongruous results, which likely is due to the use of different model systems to study the same question. 
| T-lymphocytes

T-lymphocytes (Tregs). P aeruginosa infection may also stimulate
Th2 and Th17 cells. In CF, there appears to be an imbalance between Th17 cells and Tregs. How much of this imbalance is due to abnormal CFTR function versus the airway environment is unknown. Tregs are reduced in CFTR knockout mice compared to WT mice, and this decrease appears to be related to a deficiency in indoleamine 2,3-dioxygenase. 105 Tregs were also decreased in people with CF in a small study, and the number of Tregs correlated with lung function. 106 In a larger more recent study, the absolute number and the percentage of Tregs were decreased in the peripheral circulation in people with CF compared to people without CF. 107 Tregs were also decreased in BAL fluid from people with CF compared to disease controls. Interestingly, the number of Tregs positively correlated with lung function measurements in people with CF. 107 P aeruginosa also affected Tregs in CF. People with CF who were chronically infected with P aeruginosa FIGURE 2 Environmental triggers such as infection induce M0 macrophages to polarize into the M1 (pro-inflammatory phenotype). As infection status changes, macrophages are able to class switch between the pro-inflammatory M1 phenotype and the anti-inflammatory M2 phenotype. A balance between the macrophage sub-populations is important for appropriate activation and resolution of the inflammatory response. In CF, infection induces the M1 phenotype; however, the unique environment of the CFTR deficient lung dysregulates the balance between M1 and M2 macrophages contributing to persistent inflammation. In addition, receptor patterns are altered leading to increased proinflammatory signaling and ineffective phagocytosis and efferocytosis. cav-1, caveolin-1; CCL2, C-C motif chemokine ligand 2; CD, cluster of differentiation; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN, interferon; IL, interleukin; MAPK, mitogen-activated protein kinase; MARCO, macrophage receptor with collagenous structure; MHC, major histocompatibility complex; NF-κB, nuclear factor-kappaB; RANTES, regulated on activation normal T-cell expressed, and secreted; TLR, toll-like receptor; TNF, tumor necrosis factor 
| Anti-inflammatory therapies
Arguably, the primary goal of studying inflammation in CF is to develop safe and effective anti-inflammatory therapies. It is unclear to what degree CFTR modulators will impact the inflammatory response. 49, 56 CFTR modulators are unlikely to fully reverse structural damage that is already present in people with established disease. Furthermore, while the burden of P aeruginosa may decrease in the first 6 months of modulator therapy, it may rebound thereafter. 56 In this situation, the inflammatory response is likely to increase as well. From these observations, one can predict that people with CF, regardless of modulator use, will benefit from effective anti-inflammatory therapy.
Until therapies are developed that are proven to effectively prevent or reverse lung disease, research into inflammation and anti-inflammatory drug development must continue. In this era, it will be important to study not only how drugs targeting CFTR function improve airway clearance and infection, but also to determine what impact they will have on the inflammatory state.
The inflammatory response in the CF lung is complex and closely interrelated with other CF-associated airway abnormalities. Caution must be used when developing anti-inflammatory drugs for CF so as not to exacerbate the co-existing bacterial infection. A large Phase II/III clinical trial of a LTB 4 receptor antagonist was stopped early because of increased frequency of pulmonary exacerbations in adults, but not children, who received the investigational product. 108 The increase in pulmonary exacerbations likely occurred because the effect of that drug was too great. Subsequent studies in mice found that lower doses of the drug attenuated the inflammatory response without exacerbating the infection, but high doses, like the dose used in the clinical trial, overly suppressed the inflammatory response and were associated with increased bacterial colony counts. 109 While the clinical trial results provide a warning to the CF research community regarding anti-inflammatory drug development, the mouse data highlight the potential value of studying anti-inflammatory drugs in disease-relevant animal models before proceeding to clinical trials in humans. Because anti-inflammatory drugs pose unique challenges in CF, the Cystic Fibrosis Foundation established a working group to develop guidelines for anti-inflammatory drug development. These guidelines were published in a white paper in 2015. 110 The working group concluded that preclinical safety studies must be conducted in disease-relevant models before bringing new anti-inflammatory drugs to clinical trial.
Although safety must be first established in adults, subsequent studies should include children because they are most likely to receive the greatest benefit from anti-inflammatory drugs. The working group also recommended that pharmacokinetic-pharmacodynamic studies and early-phase safety studies be performed before proceeding to larger studies of longer duration. The working group realized that novel study criteria. 113, 114 The difficulty with utilizing the Fuchs' criteria is that it S40 | was not originally designed to define a pulmonary exacerbation prospectively, but rather, it was developed for post hoc use in a clinical trial to determine why clinicians prescribed antibiotics. Furthermore, the number of subjects required to enroll in a clinical trial using the frequency of pulmonary exacerbations as an outcome measure would be quite large. 111 With the advent of new therapies, especially CFTR modulators, the frequency of pulmonary exacerbations is decreasing, and thus the number of subjects required to enroll in an antiinflammatory clinical trial in the current era will be even larger.
Enrolling people with a history of pulmonary exacerbations in the previous 12 months may help to enrich the study population. However,
given that the goal of anti-inflammatory therapy is to slow lung disease progression and maintain health in patients with minimal or no disease, the question then arises as to what is the most appropriate population to enroll in clinical trials of anti-inflammatory drugs?
Ultimately, it can be challenging to conduct large clinical trials in CF in which the available study population is relatively small.
Determining which anti-inflammatory drugs should move forward to larger, longer trials can be difficult, and investigators have been searching for a way to screen compounds using a biomarker-based approach so that only the most promising candidates advance. This approach, in part, led to the low hanging fruit project that was commissioned by the Cystic Fibrosis Foundation several years ago. In this project, clinically approved anti-inflammatory drugs were studied in CF. Changes in sputum inflammatory markers obtained via induction were analyzed before and after study participants took an antiinflammatory drug for 28 days. The drugs under study included methotrexate, hydroxychloroquine, simvastatin, and pioglitazone.
Ibuprofen was used as a positive control because it is the only recommended anti-inflammatory drug for CF. 115, 116 Unfortunately, none of the drugs, including ibuprofen, demonstrated a significant change in pertinent sputum biomarkers. [117] [118] [119] [120] [121] The reasons for these results are not clear. With the exception of ibuprofen, in which pharmacokinetics demonstrated that subjects were receiving adequate doses, the dosing of other drugs may have been inadequate to impact the inflammatory response in the CF airway. The dosage for these drugs was chosen based on the high end of the recommended dose range used to treat the conditions for which they were approved originally. These doses may have been insufficient to impact CF airway inflammation. Another explanation could be that regional differences in CF lung disease and variability in sputum measurements may have been too great to detect a difference in a small, short clinical trial.
Finally, the study duration may have been too short to detect a change in sputum biomarkers.
Two clinical trials of a monoclonal antibody directed toward the type III secretion system of P aeruginosa in CF might provide some insight into the minimal time necessary to see a change in biomarkers secondary to anti-inflammatory drugs. 122, 123 In a Phase IB trial of a single dose of the monoclonal antibody KB001, investigators saw a statistically significant decrease in sputum free elastase and trends toward decreased sputum IL-1β and IL-8 four weeks after the infusion of study drug. 122 In a subsequent 20-week Phase II study, subjects received five doses of KB001-A during the first 12 weeks. 123 No change in the frequency of pulmonary exacerbation or time to exacerbations was detected. There was no difference in FEV 1 over the first 12 weeks of the study, but the FEV 1 curves began to separate at 16 weeks. With respect to sputum biomarkers, every inflammatory mediator evaluated tended to decrease by 16 weeks, becoming statistically significant for IL-8, thereby suggesting that 12-16 weeks is necessary to begin to detect differences in sputum markers. However, the observed effect size and variability indicate that even a 16-week study would still require a large number of subjects to detect statistically significant differences in sputum markers. This calls into question the utility of using sputum biomarkers as method for screening anti-inflammatory drugs. In the low hanging fruit project, ibuprofen did demonstrate a statistically significant decrease in sputum IL-6 concentration and a trend toward decreased sputum neutrophils. 117 The limited changes in efficacy markers seen in the clinical trial of ibuprofen leads to several questions. If a biomarkerbased approached for screening had been employed when ibuprofen was being considered for a clinical trial in CF, would changes in sputum IL-6 have been enough to move forward? Is it possible that other drugs in the low-hanging fruit project might have made an impact clinically but were discounted due to their inability to demonstrate a change in sputum biomarkers? Although one cannot currently advocate for using sputum biomarkers as a method for screening anti-inflammatory drugs, they may be useful as exploratory outcomes in future clinical trials.
Furthermore, while finding a change in sputum biomarkers would be encouraging for subsequent drug development, these results must be interpreted with caution and decisions on future drug development should not rest solely on this outcome.
Several anti-inflammatory drugs have been evaluated in preclinical models of CF, and many have advanced to human trials (Table 1) .
However, a comprehensive review of anti-inflammatory therapy in CF is beyond the scope of this manuscript. Below we present antiinflammatory therapies that have been or may soon be considered for CF. Several other potential immunomodulatory therapies are not included here but remain worthy of further investigation.
| Ibuprofen
In 1995, Konstan et al first showed that individuals taking high-dose ibuprofen over a period of 4 years had slower annual rate of change in FEV 1 than those taking placebo. 112 A later analysis of the CFFPR confirmed that people with CF who took high-dose ibuprofen had a reduced rate of lung function decline over a 7-year period compared to those individuals with CF who never took ibuprofen. 124 Although it had been inferred that treatment-associated reduction in FEV 1 decline seen with high-dose ibuprofen ultimately would improve survival, no such relationship had been described for any chronic cystic fibrosis therapy prior to Konstan et al in 2018. 125 Konstan et al recently examined the associations between high-dose ibuprofen treatment, the reduction in rate of FEV 1 decline, and mortality among children and it induced extension of microtubules to the periphery of the cell. 132 Ibuprofen also restored microtubule-dependent intracellular transport. These effects likely occur through an AMPK-related pathway. 132 Because ibuprofen has not been widely adopted due to logistical issues associated with obtaining 3-hour pharmacokinetic testing and concerns over potential adverse effects, 133 it is important to determine its molecular mechanism of action so that similar antiinflammatory drugs are able to be developed for CF.
| Acebilustat
Acebilustat (CTX-4430) is a once-daily oral inhibitor of LTA 4 hydrolase that prevents the formation of LTB 4 , a potent neutrophil chemoattractant. It also has been suggested that when LTA 4 hydrolase is blocked, substrates are shunted down the metabolic pathway to produce the pro-resolving lipid mediator LXA 4 . In pharmacokinetic and pharmacodynamic studies of acebilustat, there was no difference between people with CF and healthy volunteers. 134 Further, LTB 4 S42 | production was reduced in the blood of both CF and non-CF study participants and in the sputum of CF patients. In an early phase study, 17 adults with mild to moderate CF received either acebilustat (50 or 100 mg) or placebo once daily for 15 days. 135 Significant reductions in sputum neutrophil counts and sputum elastase were observed with acebilustat treatment. Acebilustat was found to be safe and well tolerated. 135 These results led to a subsequent Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of CTX-4430 (acebilustat) administered orally once-daily for 48 weeks in adults with CF (NCT02443688). The last person is expected to the complete the study in early summer 2018 with results expected later that year. 
| Lenabasum
| Inhibitors of neutrophil elastase
The CF airway contains massive quantities of free elastase, which has multiple deleterious effects in addition to damaging the host airway wall structure. The search for safe and effective elastase inhibitors has continued for decades. The problem to date has been the inability to produce enough of the inhibitor to deposit in the airways in sufficient quantities to bind all of the free neutrophil elastase.
Two doses of an inhaled alpha1-proteinase inhibitor (Alpha-1 HC)
were studied for 3 weeks in 30 adults with CF in a Phase IIa randomized, double-blind, placebo-controlled multicenter clinical trial. 143 There was a dose-dependent increase in the sputum alpha1-PI at the end of treatment, and AEs and SAEs were balanced across groups. No difference in lung function was observed in this small study population over a fairly short length of time in this early phase trial, but Alpha-1 HC was safe and well-tolerated. 143 This drug is a highly purified blood product and, unfortunately, it was not moved forward, perhaps based more on logistical or financial decisions than a lack of scientific support from this early phase clinical trial. 
| (R)-Roscovitine
(R)-Roscovitine is a cyclin-dependent kinase inhibitor that restores surface expression and function of F508del mutant CFTR. 144 In human CF cells, roscovitine partially inhibited the interaction between F508del-CFTR and calnexin by depleting calcium in the endoplasmic reticulum, and it inhibited the proteasome activity in a calciumindependent manner. 144 Roscovitine also rescued acidification of phagolysosomes in alveolar macrophages to improve their bactericidal activity, 145 induced neutrophil apoptosis, 146 and restored the Th17/ Th2 balance. 147 Roscovitine may have a potential therapeutic benefit in CF. 148, 149 A Phase II, dose-ranging, multicenter, double-blind, placebo-controlled study to evaluate the safety and efficacy of (R)-Roscovitine in 36 adults with at least one copy of F508del and chronically infected with P aeruginosa is being conducted in France (NCT02649751).
| Thymosin α-1
Thymosin α-1 (Tα1) is a naturally occurring polypeptide that has been used worldwide as an immunomodulatory drug for several diseases. hepcidin, and lipcalin-2 (Lcn2). 156 In pre-clinical murine models of sepsis, marked reduction in colony forming unites (CFUs) and improved phagocytic activity and survival were seen in the human MSC treated mice compared to control mice. 157, 158 In a study using WT and CFTR knockout mice, BAL fluid from CF mice had significantly higher CFUs than WT mice after infection with P aeruginosa or S aureus. CFUs were significantly decreased with human MSC therapy in both models. 159 Antimicrobial effectiveness of the human MSCs supernatants also enhanced the effectiveness of antibiotics used to treat these infections. Taken CF. 163, 164 Several studies have been completed and most demonstrate clinical benefit of azithromycin over placebo. [165] [166] [167] [168] Notably, relatively large studies of up to 6 months duration in both P aeruginosa infected and non-infected subject populations resulted in significant reductions in the risk of acute pulmonary exacerbation. 165, 168 In those subjects infected with P aeruginosa, there was also a significant increase in lung function based on FEV 1 . To what degree this improvement occurs through the immunomodulatory properties of these antibiotics versus the antimicrobial effects is uncertain. Azithromycin is remarkably able to concentrate and persist in the airway-particularly within airway leukocytes. [169] [170] [171] [172] [173] [174] More recent laboratory research shows that azithromycin, when tested in media environments more similar to the mammalian airway, can inhibit growth or even kill relevant bacteria such as P aeruginosa or other Gram-negative pathogens at physiologically relevant concentrations. [175] [176] [177] Others report that azithromycin primes the host immune response to better resist viral infection. Unless such work is completed and finds a lack of benefit, it is likely that chronic azithromycin will appropriately remain the most commonly prescribed therapy in CF that is intended to modulate or reduce the host inflammatory response. and effective anti-inflammatory drugs for CF lung disease is an important and largely unmet clinical need.
Science and therapeutic discovery in CF continue to advance at an impressive pace, and our patients are likely to benefit greatly from this progress in the coming years. Most investigators firmly believe that the host inflammatory response will remain a key therapeutic target even for those patients who benefit from highly effective CFTR enhancing therapies. Ongoing research to identify and validate biomarkers of antiinflammatory effect in CF populations, partnered with a clear understanding of the necessary clinical outcome measures in the post-modulator era, will be important to continue the recent momentum in this area.
